• Contact us
  • Advertise with us
  • Login
Tashi Pharma
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
No Result
View All Result
Home Indian Pharma News

Colorcon opens New Containment Suite for Handling High Potency APIs at its Global Technical Center in Harleysville, USA

PRN by PRN
May 21, 2021
in Indian Pharma News
32 1
0
Colorcon opens New Containment Suite for Handling High Potency APIs at its Global Technical Center in Harleysville, USA
21
SHARES
50
VIEWS

Colorcon announced the expansion of its technical service capabilities with a new Containment Suite located in our Global Headquarters in Harleysville, PA, USA.

Alongside big pharma, there are a growing number of virtual or small companies developing drug products that don’t necessarily have their own lab capabilities or resources to progress their products into the clinic. The Containment Suite provides the capability to develop prototype tablet or capsule dosage forms for clients when active pharmaceutical ingredient (API) quantity is limited and/or the API potency requires a higher level of protection. The lab utilizes mobile isolation modules to offer maximum process flexibility.

Kurt Fegely, Managing Director, Colorcon Americas, states “investing in this facility demonstrates Colorcon’s continued commitment to supporting pharmaceutical development in North America, reducing our customer’s time to market and reflects our dedication to providing unparalleled products and services. We can now offer a complete cycle starting from the customer’s API, all the way to a finished coated dosage form within our facilities and provide prototypes ready for customer evaluation.”

Charlie Cunningham, Technical Director, explains the importance of the facility, “Many of our customers, especially in early development phase work with very small quantities of active ingredients, which can have unknown safety profiles and can also be extremely costly and limited in availability. Our investment in the best equipment enables us to produce tablets and capsules with milligrams of active product in the safest of conditions.”

With our understanding of excipients and coatings, Colorcon can support early phase screening activity, providing both big pharma and virtual or small companies access to our formulators, equipment, and services as well as generating non-GMP prototypes of the dosage form for subsequent clinical supply.

Colorcon’s continued investment in customer support is unmatched in the industry; this expanded facility with new capabilities and professional expertise means that they can help developers as they manage through the challenges they face today and in the years ahead.

Tags: Colorcon
Previous Post

Cipla launches ‘ViraGen’ a polymerase chain reaction (Covid-19 RT-PCR) test

Next Post

J. B. Chemicals and Pharmaceuticals Ltd – legacy continues……

PRN

PRN

Related Posts

Zydus to launch Oxemia
Indian Pharma News

Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)

by admin
March 7, 2022
FDA Urges Companies to be 'Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls
Indian Pharma News

US FDA Urges Companies to be ’Recall Ready’ to Protect Public Health

by admin
March 6, 2022
Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan
Indian Pharma News

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

by admin
March 5, 2022
Themis Medicare receives approval for immunomodulatory antiviral drug from DCGI
Indian Pharma News

Themis Medicare receives approval for immunomodulatory antiviral drug from DCGI

by admin
March 4, 2022
Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution
Indian Pharma News

Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution

by admin
March 3, 2022
Next Post
J.B.Chemicals & Pharmaceuticals Ltd

J. B. Chemicals and Pharmaceuticals Ltd - legacy continues......

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

Zydus to launch Oxemia

Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)

March 7, 2022
FDA Urges Companies to be 'Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

US FDA Urges Companies to be ’Recall Ready’ to Protect Public Health

March 6, 2022
FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

March 5, 2022
Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

US FDA publishes guidance on Initiation of Voluntary Recalls

March 5, 2022
Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

March 5, 2022

Browse by Category

  • Articles
  • Company Focus
  • EDQM
  • EMA
  • European Commision
  • Global Pharma News
  • Guideline News
  • Health Canada
  • Indian Pharma News
  • Interview
  • Medsafe
  • MHRA
  • SAHPRA
  • US FDA
  • Webinar

Browse by Tags

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Contact us

Address:Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002.
Phone:+91 8511586232, +91 9029066605
Email:author@pharmaregnews.com

Browse by Tag

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Advertise with us

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • bioanalytical
    • Clinical
  • Webinar
  • Contact us
  • Advertise with us
  • Login

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?